About Us

FSD Pharma Growth Strategy

  • Pursue further acquisition targets or potential investments that are unique and align with our mission of Total Brain Health
  • Begin the process of advancing clinical trials for its compound Lucid-MS, for the novel treatment of progressive MS (Multiple Sclerosis)
  • Begin the process of advancing clinical trials for the treatment of depression, anxiety and psychiatric disorders through its psychedelic molecule Lucid-Psych
  • Advancement of FSD-PEA for phase 2 trials, after selecting a suitable clinical indication
  • Liquidate surplus real estate and strengthen cash position

Comparable Companies

as of October 10th, 2021